New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
11:08 EDTTROVTrovagene says diagnostic platform demonstrates ability to monitor mutations
Clinical study results presented at the American Association for Cancer Research Annual Meeting demonstrate the ability of Trovagene's molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients, the company said. Of the 33 patients enrolled in the study, Trovagene's BRAF V600E oncogene mutation assay was able to identify the mutation in 29 patients, or 88%, at any time point during the study, demonstrating a high level of concordance with tissue biopsy. In addition, 25 of the 33 patients, or 76%, were positively identified for the mutation with their first urine sample. Mark Erlander, Ph.D., chief scientific officer of Trovagene, stated, "The concordance shown between our platform and tissue biopsy in this study are encouraging, especially when we consider that different patients will show response to treatments at different times."
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:08 EDTTROVTrovagene expands program with study evaluating cancer monitoring platform
Trovagene announced that it has expanded its clinical program to include a study designed to evaluate use of the company's precision cancer monitoring technology in the management of lung cancer patients. The primary objective of the study is to detect and monitor EGFR mutations in urine, plasma and tissue to determine concordance. Secondary objectives include correlating quantitative EGFR mutational load over time with tumor burden, and demonstrating detection of the resistant EGFR T790M mutation prior to clinical or radiographic progression in lung cancer patients treated with tyrosine kinase inhibitor therapy. Approximately 225 patients are anticipated to be enrolled in the study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use